FDA approved Adcetris, Revlimid, and Rituxan for relapsed/refractory LBCL patients ineligible for auto-HSCT or CAR-T therapy, based on ECHELON-3 trial results. The combination therapy showed ...
After receiving radiation therapy for uterine cancer, you may experience fertility challenges, vaginal dryness, and bowel or bladder problems. Options to manage and relieve your side effects can vary.
Treanda (bendamustine) may be an effective substitute for CHOP as the chemotherapy partner to Rituxan (rituximab) for patients receiving initial therapy for advanced follicular or mantle cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results